Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.

What Was Tested

The paper reports a study of Enalapril, published as a randomized controlled trial.

However, no data are presently available about the effects of antihypertensive therapy on vascular structure in hypertensive patients with NIDDM.

Therefore, the researchers have investigated the effect of an angiotensin-converting enzyme inhibitor, enalapril, and a highly selective angiotensin receptor blocker, candesartan cilexetil, on indices of subcutaneous small resistance artery structure in 15 patients with mild hypertension and NIDDM.

Who Took Part

According to the abstract, 15 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Small arteries were dissected and mounted on a micromyograph and the media-to-internal lumen ratio was evaluated; moreover, endothelium-dependent vasodilation to acetylcholine was assessed.

How the Study Was Run

In design terms this was a randomized and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Enalapril and who got the comparison, which limits bias.

The Enalapril group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Arteries, Benzimidazoles, Biphenyl Compounds, Diabetes Mellitus, Type 2 and Echocardiography.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Enalapril in 15 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: all human trials.